EMA recommended 17 drugs for marketing authorization in December, including treatments for rare heart conditions, anemia, and liver disease.

Nat Clin Pract Urol. 2009;6(2):74-75. Clinical benefit is only one facet of clinical decision making; medical risks and financial costs also need to be considered. For example, many of the ...